JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

60.47 3.17

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.53

Макс.

60.79

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

-3.35% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.1B

3.7B

Предыдущая цена открытия

57.3

Предыдущая цена закрытия

60.47

Новостные настроения

By Acuity

50%

50%

186 / 347 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 апр. 2026 г., 23:08 UTC

Отчет

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 23:07 UTC

Отчет

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 22:20 UTC

Отчет

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 апр. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

30 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 апр. 2026 г., 23:27 UTC

Обсуждения рынка

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 апр. 2026 г., 23:22 UTC

Отчет

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 апр. 2026 г., 23:20 UTC

Обсуждения рынка

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 апр. 2026 г., 22:52 UTC

Отчет

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 22:33 UTC

Отчет

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 апр. 2026 г., 22:32 UTC

Отчет

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 апр. 2026 г., 22:32 UTC

Отчет

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 апр. 2026 г., 22:24 UTC

Приобретения, слияния, поглощения

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 апр. 2026 г., 22:05 UTC

Отчет

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 апр. 2026 г., 21:57 UTC

Отчет

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 апр. 2026 г., 21:56 UTC

Отчет

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 апр. 2026 г., 21:56 UTC

Отчет

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 апр. 2026 г., 21:55 UTC

Отчет

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 апр. 2026 г., 21:54 UTC

Отчет

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 апр. 2026 г., 21:54 UTC

Отчет

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 апр. 2026 г., 21:53 UTC

Отчет

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 апр. 2026 г., 21:49 UTC

Отчет

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 апр. 2026 г., 21:49 UTC

Отчет

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

-3.35% падение

Прогноз на 12 месяцев

Средняя 54.8 USD  -3.35%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

186 / 347Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat